This CME program will highlight recent advances in the treatment and management of irritable bowel syndrome, through the lens of primary care. The expert faculty, Dr. Brooks Cash, will first discuss pathophysiology and current diagnostic criteria in irritable bowel syndrome (IBS), including the distinctions between IBS-C and IBS-D. Following, recent clinical trial data will be analyzed, with an emphasis on practical applications of available therapeutic options to manage patients with IBS. At the conclusion of this education, clinicians will gain insight into best practices for utilizing long-term pharmacologic and non-pharmacologic strategies to improve outcomes and quality of life in patients with irritable bowel syndrome.
Primary care providers, advanced practice providers and other healthcare professionals who manage patients with IBS
Assess the symptoms, pathophysiology, and diagnostic strategies for irritable bowel syndrome, as well as distinguishing IBS-C from IBS-D
Review the current clinical trial data and practical applications of available therapeutic options to manage patients with IBS
Evaluate long-term pharmacologic and non-pharmacologic strategies to manage symptoms and quality of life in patients with IBS
Foundational Review of Irritable Bowel Syndrome C and D; Pathophysiology, Symptoms, Diagnosis, and Therapeutic Options
Clinical Trial Review and Practical Applications of IBS-D
Clinical Trial Review and Practical Applications of IBS-C
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty
have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Brooks D. Cash, MD | Speaker’s Bureau/Consultant: AbbVie Inc.; Ardelyx; AstraZeneca; Alnylam Pharmaceuticals, Inc.; Salix Pharmaceuticals; QoL |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC, Nicole McMenamin and Chelsey Simonds hereby state that they do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by educational grants from Salix Pharmaceuticals and Ironwood.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME, Salix Pharmaceuticals and Ironwood do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
